Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 156

1.

Comparative effectiveness of the hepatitis C virus protease inhibitors boceprevir and telaprevir in a large U.S. cohort.

Backus LI, Belperio PS, Shahoumian TA, Cheung R, Mole LA.

Aliment Pharmacol Ther. 2014 Jan;39(1):93-103. doi: 10.1111/apt.12546. Epub 2013 Nov 10.

PMID:
24206566
[PubMed - indexed for MEDLINE]
2.

Early virologic responses and hematologic safety of direct-acting antiviral therapies in veterans with chronic hepatitis C.

Belperio PS, Hwang EW, Thomas IC, Mole LA, Cheung RC, Backus LI.

Clin Gastroenterol Hepatol. 2013 Aug;11(8):1021-7. doi: 10.1016/j.cgh.2013.03.006. Epub 2013 Mar 21.

PMID:
23524130
[PubMed - indexed for MEDLINE]
3.

Effectiveness of telaprevir or boceprevir in treatment-experienced patients with HCV genotype 1 infection and cirrhosis.

Hézode C, Fontaine H, Dorival C, Zoulim F, Larrey D, Canva V, De Ledinghen V, Poynard T, Samuel D, Bourliere M, Alric L, Raabe JJ, Zarski JP, Marcellin P, Riachi G, Bernard PH, Loustaud-Ratti V, Chazouilleres O, Abergel A, Guyader D, Metivier S, Tran A, Di Martino V, Causse X, Dao T, Lucidarme D, Portal I, Cacoub P, Gournay J, Grando-Lemaire V, Hillon P, Attali P, Fontanges T, Rosa I, Petrov-Sanchez V, Barthe Y, Pawlotsky JM, Pol S, Carrat F, Bronowicki JP; CUPIC Study Group.

Gastroenterology. 2014 Jul;147(1):132-142.e4. doi: 10.1053/j.gastro.2014.03.051. Epub 2014 Apr 3.

PMID:
24704719
[PubMed - indexed for MEDLINE]
4.

Direct-acting antiviral therapies for hepatitis C genotype 1 infection: a multiple treatment comparison meta-analysis.

Cooper C, Lester R, Thorlund K, Druyts E, El Khoury AC, Yaya S, Mills EJ.

QJM. 2013 Feb;106(2):153-63. doi: 10.1093/qjmed/hcs214. Epub 2012 Nov 17.

PMID:
23159839
[PubMed - indexed for MEDLINE]
Free PMC Article
5.

Telaprevir versus boceprevir in chronic hepatitis C: a meta-analysis of data from phase II and III trials.

Sitole M, Silva M, Spooner L, Comee MK, Malloy M.

Clin Ther. 2013 Feb;35(2):190-7. doi: 10.1016/j.clinthera.2012.12.017. Epub 2013 Jan 29.

PMID:
23369368
[PubMed - indexed for MEDLINE]
6.

UK consensus guidelines for the use of the protease inhibitors boceprevir and telaprevir in genotype 1 chronic hepatitis C infected patients.

Ramachandran P, Fraser A, Agarwal K, Austin A, Brown A, Foster GR, Fox R, Hayes PC, Leen C, Mills PR, Mutimer DJ, Ryder SD, Dillon JF.

Aliment Pharmacol Ther. 2012 Mar;35(6):647-62. doi: 10.1111/j.1365-2036.2012.04992.x. Epub 2012 Feb 1.

PMID:
22296568
[PubMed - indexed for MEDLINE]
7.

[Side-effects of pegylated interferon plus ribavirin therapy with or without protease inhibitor direct acting antiviral agents during treatment of chronic hepatitis C virus infection].

Hunyady B, Kovács B, Battyáni Z.

Orv Hetil. 2011 Dec 11;152(50):1997-2009. doi: 10.1556/OH.2011.29266. Review. Hungarian.

PMID:
22112373
[PubMed - indexed for MEDLINE]
8.

Boceprevir: a protease inhibitor for the treatment of hepatitis C.

Chang MH, Gordon LA, Fung HB.

Clin Ther. 2012 Oct;34(10):2021-38. doi: 10.1016/j.clinthera.2012.08.009. Epub 2012 Sep 11. Review.

PMID:
22975763
[PubMed - indexed for MEDLINE]
9.

Efficacy of boceprevir, an NS3 protease inhibitor, in combination with peginterferon alfa-2b and ribavirin in treatment-naive patients with genotype 1 hepatitis C infection (SPRINT-1): an open-label, randomised, multicentre phase 2 trial.

Kwo PY, Lawitz EJ, McCone J, Schiff ER, Vierling JM, Pound D, Davis MN, Galati JS, Gordon SC, Ravendhran N, Rossaro L, Anderson FH, Jacobson IM, Rubin R, Koury K, Pedicone LD, Brass CA, Chaudhri E, Albrecht JK; SPRINT-1 investigators.

Lancet. 2010 Aug 28;376(9742):705-16. doi: 10.1016/S0140-6736(10)60934-8. Epub 2010 Aug 6. Erratum in: Lancet. 2010 Oct 9;376(9748):1224. SPRINT-1 investigators [added]; multiple investigator names added.

PMID:
20692693
[PubMed - indexed for MEDLINE]
10.

Safety and efficacy of protease inhibitors to treat hepatitis C after liver transplantation: a multicenter experience.

Coilly A, Roche B, Dumortier J, Leroy V, Botta-Fridlund D, Radenne S, Pageaux GP, Si-Ahmed SN, Guillaud O, Antonini TM, Haïm-Boukobza S, Roque-Afonso AM, Samuel D, Duclos-Vallée JC.

J Hepatol. 2014 Jan;60(1):78-86. doi: 10.1016/j.jhep.2013.08.018. Epub 2013 Aug 29.

PMID:
23994384
[PubMed - indexed for MEDLINE]
11.

Triple therapy with first generation HCV protease inhibitors: lead-in or no lead-in phase?

Pascale A, Serfaty L.

J Hepatol. 2013 Feb;58(2):391-4. doi: 10.1016/j.jhep.2012.09.023. Epub 2012 Oct 9.

PMID:
23063419
[PubMed - indexed for MEDLINE]
Free Article
12.

Telaprevir or boceprevir triple therapy in patients with chronic hepatitis C and varying severity of cirrhosis.

Saxena V, Manos MM, Yee HS, Catalli L, Wayne E, Murphy RC, Shvachko VA, Pauly MP, Chua J, Monto A, Terrault NA.

Aliment Pharmacol Ther. 2014 May;39(10):1213-24. doi: 10.1111/apt.12718. Epub 2014 Mar 24.

PMID:
24654657
[PubMed - indexed for MEDLINE]
13.

Peg-IFNα/ribavirin/protease inhibitor combination in hepatitis C virus associated mixed cryoglobulinemia vasculitis: results at week 24.

Saadoun D, Resche Rigon M, Thibault V, Longuet M, Pol S, Blanc F, Pialoux G, Karras A, Bazin-Karra D, Cazorla C, Vittecoq D, Musset L, Decaux O, Ziza JM, Lambotte O, Cacoub P.

Ann Rheum Dis. 2014 May;73(5):831-7. doi: 10.1136/annrheumdis-2012-202770. Epub 2013 Apr 20.

PMID:
23606708
[PubMed - indexed for MEDLINE]
Free PMC Article
14.

Cost effectiveness of direct-acting antiviral therapy for treatment-naive patients with chronic HCV genotype 1 infection in the veterans health administration.

Chan K, Lai MN, Groessl EJ, Hanchate AD, Wong JB, Clark JA, Asch SM, Gifford AL, Ho SB.

Clin Gastroenterol Hepatol. 2013 Nov;11(11):1503-10. doi: 10.1016/j.cgh.2013.05.014. Epub 2013 May 22.

PMID:
23707354
[PubMed - indexed for MEDLINE]
15.

Telaprevir: a review of its use in the management of genotype 1 chronic hepatitis C.

Perry CM.

Drugs. 2012 Mar 26;72(5):619-41. doi: 10.2165/11208370-000000000-00000. Review.

PMID:
22439668
[PubMed - indexed for MEDLINE]
16.

Impact of HCV protease-inhibitor-based triple therapy for chronic HCV genotype 1 infection.

Ferenci P, Reddy KR.

Antivir Ther. 2011;16(8):1187-201. doi: 10.3851/IMP1934. Review.

PMID:
22155901
[PubMed - indexed for MEDLINE]
17.

Impact of ribavirin on HCV replicon RNA decline during treatment with interferon-α and the protease inhibitors boceprevir or telaprevir.

Hofmann WP, Chung TL, Osbahr C, Susser S, Karey U, Mihm U, Welsch C, Lötsch J, Sarrazin C, Zeuzem S, Herrmann E.

Antivir Ther. 2011;16(5):695-704. doi: 10.3851/IMP1821.

PMID:
21817191
[PubMed - indexed for MEDLINE]
18.

New triple therapy for chronic hepatitis C: real life clinical experience in a community setting.

Akiyama MJ, Piotrowski JI, Roytman MM, Chan SM, Hong LK, Huddleston L, Trujillo R, Tsai NC.

Hawaii J Med Public Health. 2013 Sep;72(9 Suppl 4):6-13.

PMID:
24052911
[PubMed - indexed for MEDLINE]
Free PMC Article
19.

[Efficacy and safety of a protease inhibitor with pegylated interferon and ribavirin in patients with untreated chronic hepatitis C: a meta analysis].

Yuan XL, Li MY, Zhang DZ.

Zhonghua Gan Zang Bing Za Zhi. 2012 May;20(5):357-62. doi: 10.3760/cma.j.issn.1007-3418.2012.05.011. Chinese.

PMID:
22971281
[PubMed - indexed for MEDLINE]
20.

A population approach to disease management: hepatitis C direct-acting antiviral use in a large health care system.

Belperio PS, Backus LI, Ross D, Neuhauser MM, Mole LA.

J Manag Care Spec Pharm. 2014 Jun;20(6):533-40.

PMID:
24856591
[PubMed - indexed for MEDLINE]
Free Article
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk